Page last updated: 2024-08-22

camptothecin and pki 166

camptothecin has been researched along with pki 166 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bar-Eli, M; Fan, D; Fidler, IJ; Kerbel, RS; Kim, SJ; Kuwai, T; Nakamura, T; Sasaki, T; Villares, GJ; Wang, H; Zigler, M1

Other Studies

1 other study(ies) available for camptothecin and pki 166

ArticleYear
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
    Neoplasia (New York, N.Y.), 2008, Volume: 10, Issue:5

    Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cecum; Cell Proliferation; Colonic Neoplasms; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Necrosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; RNA, Small Interfering; Topoisomerase I Inhibitors; Transforming Growth Factor alpha

2008